AltruBio is a privately held biotechnology company headquartered in the San Francisco Bay Area that is focused on developing novel therapeutics for the treatment of immunological diseases with high unmet medical needs. The company has leveraged its deep understanding of the role PSGL-1 plays as an immune checkpoint regulator protein to develop a platform for T-cell mediated immunological diseases.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 04/15/21 | $63,000,000 | Series A |
aMoon BVF Partners CAM Capital | undisclosed |
| 05/21/24 | $225,000,000 | Series B |
aMoon Blackstone Multi-Asset Investing BVF Partners Cormorant Asset Management RA Capital Management Soleus Capital | undisclosed |
